CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval

CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension.

Readers respond to essays on long Covid, hypochondria, and more

First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care

June 22, 2024

CDC: Deaths From Counterfeit Pills Rising

Fatal overdoses from counterfeit pharmaceuticals, particularly pills found to contain fentanyls, more than doubled in recent years, the CDC reported. Among more than 100,000 recent

September 1, 2023

Pulling back the curtain on psychiatric hospital joint ventures

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in

July 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.